| Autor: |
Fernanda Bueno, Anabella Smulever, Inés Califano, Jorgelina Guerra, Andrés Del Grecco, Juan Manuel Carrera, Raúl Giglio, Manglio Rizzo, Alejo Lingua, Ana Voogd, María del Carmen Negueruela, Erika Abelleira, Fabian Pitoia |
| Rok vydání: |
2023 |
| Předmět: |
|
| Zdroj: |
Endocrine. 80:134-141 |
| ISSN: |
1559-0100 |
| DOI: |
10.1007/s12020-022-03295-2 |
| Popis: |
To present our real-life experience with dabrafenib and trametinib (D-T) treatment in patients with BRAF V600E-mutated ATC in Argentina.We included five patients from four different hospitals. The median age was 70 years, and 60% were male. The performance status at diagnosis was grade 0 in 60% and grade 2 in 40% of patients. Four patients could undergo total thyroidectomy; in one of them, surgical treatment was amenable due to the indication of D-T as neoadjuvant therapy. From the total cohort, the best response to treatment was complete response in 40%, partial response in 20%, and stable disease in 20%. The median duration of response was 20 weeks, ranging from 16 to 92 weeks. All patients experienced at least one adverse event (AE). Grade ≥3 AEs were observed in two (40%) patients. They were upper gastrointestinal bleeding and subclavian vein thrombosis. The median follow-up was 20 weeks (range: 16 to 92).This report contributes to illustrate the feasibility and effectiveness of D-T treatment in five patients with loco-regionally advanced and metastatic BRAF V600E-mutated ATC in a real-life setting. A multidisciplinary approach and rapid molecular-tailored testing are essential to begin this therapeutic option. |
| Databáze: |
OpenAIRE |
| Externí odkaz: |
|
Full text from SpringerLink